Close Menu

private financing

The company's cofounders have developed methods for analyzing genetic material from fetal trophoblast cells isolated from the cervix.

The company — develops tests for the early detection of cancer and other diseases in whole blood — is targeting C$3.7 million in a private placement financing round.

One BioMed was spun out of Singapore's Agency for Science, Technology, and Research to  develop a point-of-care diagnostic platform for infectious disease.

The company develops assays and reagents for tissue-based biomarker research and discovery including its UltiMapper line of multiplexed assays.

The firm is developing a portable, rapid MDx platform for infectious disease testing in clinics, and anticipates launching a first product in 2020.

The companies signed an agreement earlier this year to jointly develop microbiome research services for international markets including a shotgun metagenomic sequencing-based service.

The Swedish company is developing sequencing- and PCR-based tests and services that quantify aberrations in DNA, RNA, and circulating tumor DNA.

This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.

The funds will support Curetis' R&D efforts, which include partnering its Unyvero A30 RQ mid-plex diagnostics system for verification and validation testing.

Pages

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.